financetom
Business
financetom
/
Business
/
Tata Power completes sale of its defence biz to Tata Advanced Systems
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tata Power completes sale of its defence biz to Tata Advanced Systems
Nov 2, 2020 4:39 AM

Tata Power on Monday said it has completed the sale of its defence business to Tata Advanced Systems. Tata Advanced Systems is a wholly-owned subsidiary of Tata Sons. ”The sale was completed as per a Scheme of Arrangement, which was approved by the National Company Law Tribunal at Mumbai and Hyderabad in December 2019 and March 2020, respectively,” Tata Power said in a regulatory filing. The company said it is expected to receive an enterprise value of Rs 1,076 crore as an upfront payment.

Balance consideration is subject to completion of achieving certain milestones specified in the agreements, the company added. Tata Power said the sale of defence business is part of the company’s ongoing strategic plan to monetise its non-core assets and reduce overall leverage.

”The sale proceeds will help the company to reduce leverage and increase focus in the core business areas like renewable generation, distribution and new service-led businesses which will bring greater value for our shareholders,” Praveer Sinha, CEO and Managing Director, Tata Power said. Strategic Engineering Division (SED) is a non-core defence electronics division of the company, engaged in business of indigenous design, development, production, integration, supply and life cycle support of mission-critical defence systems.

The key products include manufacturing and assembling missile launchers, electronic warfare, night vision systems and gun systems. SED has three dedicated manufacturing units — Bangalore Electronic City, Vemagal in Karnataka (under construction) and an SEZ near Bengaluru (under construction).

First Published:Nov 2, 2020 1:39 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance
Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance
Dec 5, 2024
07:45 AM EST, 12/05/2024 (MT Newswires) -- Patterson Companies ( PDCO ) reported fiscal Q2 adjusted earnings Thursday of $0.47 per diluted share, down from $0.50 a year earlier. A single analyst polled by FactSet expected $0.47. Net sales for the fiscal quarter ended Oct. 26 was $1.67 billion, up from $1.65 billion a year earlier. Analysts surveyed by FactSet...
Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand
Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand
Dec 5, 2024
07:45 AM EST, 12/05/2024 (MT Newswires) -- Southwest Airlines ( LUV ) said in a regulatory filing Thursday that it increased its Q4 unit revenue growth forecast to a range of 5.5% to 7% from the previous range of 3.5% to 5.5%, citing better-than-expected leisure travel demand and revenue optimization efforts. The carrier said it now expects Q4 capacity to...
CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend
CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend
Dec 5, 2024
07:50 AM EST, 12/05/2024 (MT Newswires) -- CME Group ( CME ) said Thursday its board approved an annual variable dividend totaling $2.10 billion as well as a share repurchase program of up to $3 billion of Class A common stock. The dividend amounts to $5.80 per share and is payable Jan. 16, 2025, to shareholders of record as of...
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults
Dec 5, 2024
07:47 AM EST, 12/05/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that it has started a late-stage clinical trial to assess investigational oral antiviral COVID-19 medicines Lagevrio or molnupiravir for the treatment of adults with COVID-19 who are at high risk for disease progression. Lagevrio is being developed by Merck ( MRK ) in collaboration with Ridgeback Biotherapeutics....
Copyright 2023-2026 - www.financetom.com All Rights Reserved